selected the median variant allele fraction level of NRAS, NEF2L2, and MET mutations in ctDNA as a moderately effective factor to predict early recurrence of hepatocellular carcinoma with AUC of 0.80, while the AUC achieved 0.97 when further combined with clinical parameters, including barcelona clinic liver cancer (BCLC) stage, tumor size, and microvascular invasion (MVI).37 This evidence concerns the gene MET and liver cancer.